Antifibrotic Effects of the Dual CCR2/CCR5 Antagonist Cenicriviroc in Animal Models of Liver and Kidney Fibrosis

A 48-week randomized phase 2b study evaluating cenicriviroc versus efavirenz in treatment-naive HIV-infected adults with C-C chemokine receptor type 5-tropic virus

(2016) Melanie Thompson et al.   AIDS

Efficacy and safety study of cenicriviroc for the treatment of non-alcoholic steatohepatitis in adult subjects with liver fibrosis: CENTAUR Phase 2b study design

(2016) Scott Friedman et al.   Contemporary Clinical Trials

Pharmacokinetics, Safety, and CCR2/CCR5 Antagonist Activity of Cenicriviroc in Participants With Mild or Moderate Hepatic Impairment

(2016) E Lefebvre et al.   CTS-Clinical and Translational Science

Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening

(2016) Vlad Ratziu et al.   GASTROENTEROLOGY

Pathobiology of liver fibrosis: a translational success story

(2015) Youngmin A Lee et al.   GUT

O033 : CCR2+ infiltrating monocytes promote acetaminophen-induced acute liver injury – therapeutic implications of inhibiting CCR2 and CCL2

(2015) O. Krenkel et al.   JOURNAL OF HEPATOLOGY

Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial

(2015) Brent A Neuschwander-Tetri et al.   LANCET

Roles for Chemokines in Liver Disease

(2014) Fabio Marra et al.   GASTROENTEROLOGY

Macrophage heterogeneity in liver injury and fibrosis

(2014) Frank Tacke et al.   JOURNAL OF HEPATOLOGY

Overview of the cellular and molecular basis of kidney fibrosis

(2014) Allison A. Eddy   Kidney International Supplements

Hepatic macrophages but not dendritic cells contribute to liver fibrosis by promoting the survival of activated hepatic stellate cells in mice

(2013) Jean-Philippe Pradere et al.   HEPATOLOGY

Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis

(2013) Bart Staels et al.   HEPATOLOGY

In Vitro and in Vivo Models of Non-Alcoholic Fatty Liver Disease (NAFLD)

(2013) Giridhar Kanuri et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Unilateral ureteral obstruction: beyond obstruction

(2013) Alvaro C. Ucero et al.   INTERNATIONAL UROLOGY AND NEPHROLOGY

Characteristics and diagnosis of NAFLD/NASH

(2013) Etsuko Hashimoto et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Chronic kidney disease: global dimension and perspectives

(2013) Vivekanand Jha et al.   LANCET

A murine model for non-alcoholic steatohepatitis showing evidence of association between diabetes and hepatocellular carcinoma

(2013) Masato Fujii et al.   Medical Molecular Morphology

From NAFLD to NASH to cirrhosis—new insights into disease mechanisms

(2013) Alexander Wree et al.   Nature Reviews Gastroenterology & Hepatology

Regression of Fibrosis and Reversal of Cirrhosis in Rats by Galectin Inhibitors in Thioacetamide-Induced Liver Disease

(2013) Peter G. Traber et al.   PLoS One

CCR2 Regulates the Uptake of Bone Marrow-Derived Fibroblasts in Renal Fibrosis

(2013) Yunfeng Xia et al.   PLoS One

Hepatic recruitment of macrophages promotes nonalcoholic steatohepatitis through CCR2

(2012) Kouichi Miura et al.   AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY

Blockade of Lymphocyte Chemotaxis in Visceral Graft-versus-Host Disease

(2012) Ran Reshef et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Role of Chemokines in Acute Liver Injury

(2012) Yedidya Saiman et al.   Frontiers in Physiology

Animal models for the study of liver fibrosis: new insights from knockout mouse models

(2011) Hiromitsu Hayashi et al.   AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY

Pharmacokinetics and Pharmacodynamics of TBR-652, a Novel CCR5 Antagonist, in HIV-1-Infected, Antiretroviral Treatment-Experienced, CCR5 Antagonist-Naïve Patients

(2011) Jean-Francois Marier et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pharmacological inhibition of the chemokine CCL2 (MCP-1) diminishes liver macrophage infiltration and steatohepatitis in chronic hepatic injury

(2011) Christer Baeck et al.   GUT

Safety, Efficacy, and Pharmacokinetics of TBR-652, a CCR5/CCR2 Antagonist, in HIV-1–Infected, Treatment-Experienced, CCR5 Antagonist–Naive Subjects

(2011) Jacob Lalezari et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Antagonism of the chemokine Ccl5 ameliorates experimental liver fibrosis in mice

(2010) Marie-Luise Berres et al.   JOURNAL OF CLINICAL INVESTIGATION

CCR2 antagonism improves insulin resistance, lipid metabolism, and diabetic nephropathy in type 2 diabetic mice

(2010) Young Sun Kang et al.   KIDNEY INTERNATIONAL

Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis

(2010) Arun J. Sanyal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dual Role of CCR2 in the Constitution and the Resolution of Liver Fibrosis in Mice

(2009) Claudia Mitchell et al.   AMERICAN JOURNAL OF PATHOLOGY

CCR2 promotes hepatic fibrosis in mice

(2009) Ekihiro Seki et al.   HEPATOLOGY

PPARγ Agonist and Angiotensin II Receptor Antagonist Ameliorate Renal Tubulointerstitial Fibrosis

(2009) Jee-Young Han et al.   JOURNAL OF KOREAN MEDICAL SCIENCE

Additive antifibrotic effects of pioglitazone and candesartan on experimental renal fibrosis in mice

(2009) KEISHI HIGASHI et al.   NEPHROLOGY

The Global Impact of Hepatic Fibrosis and End-Stage Liver Disease

(2008) Young-Suk Lim et al.   Clinics in Liver Disease